Holding the Line in AML: Real-World Care Meets Breakthrough Trials
The HemOnc Pulse
00:00
Combining ziftomenib in frontline and relapse
Wang describes promising combinations with 7+3 and venetoclax‑azacitidine, showing higher responses and safety signals.
Play episode from 06:03
Transcript
